Congenital disorder of oxygen sensing: Association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors

Blood

Volumn 103, Issue 10, 2004, Pages 3924-3932

  Gordeuk, Victor R ^a   Sergueeva, Adelina I ^b   Miasnikova, Galina Y ^b   Okhotin, Daniel ^b   Voloshin, Yaroslav ^b   Choyke, Peter L ^b   Butman, John A ^b   Jedlickova, Katerina ^b   Prchal, Josef T ^b   Polyakova, Lydia A ^b  

^a HOWARD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHUVASH POLYCYTHEMIA; DISEASE ASSOCIATION; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; HEMANGIOMA; HUMAN; HYPOXIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOPHYSIOLOGY; POLYCYTHEMIA; PRIORITY JOURNAL; RUSSIAN FEDERATION; SCHOOL CHILD; THROMBOSIS; VHL GENE;

EID: 2342631195     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2535     Document Type: Article

References (43)

1. Polyakova LA. Familial erythrocytosis among inhabitants of the Chuvash ASSR. Problemi Gematologii I Perelivaniya Krovi. 1974;10:30-38.
2. Polyakova LA. Familial-Hereditary Erythrocytosis. Moscow, Russia: Scientific Research Institute of Hematology and Blood Transfusion; 1977.
3. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythemia in Chuvashia. Blood. 1997;89:2148-2154.
4. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis. 2002;28:57-62.
5. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614-621.
6. Pastore YD, Jelinek J, Ang S, et al. Mutation in the VHL gene in sporadic apparently congenital polycythemia. Blood. 2003;101:1591-1595.
7. Percy MJ, McMullin MF, Jowitt SN, et al. Chuvash-type congenital polycythemia in 4 families of Asian and Western European ancestry. Blood. 2003;102:1097-1099.
8. Pastore Y, Jedlickova K, Guan YL, et al. Mutations of von Hippel-Lindau tumor suppressor gene and congenital polycythemia. Am J Hum Genet. 2003;73:412-419.
9. Liu E, Percy MJ, Amos CI, et al. The worldwide distribution of the VHL 598CT mutation indicates a single founding event. Blood. 2003;103:1937-1940.
10. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003;111:779-783.
11. Semenza GL. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med. 2001;7:345-350.
12. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059-2067.
13. Richards FM. Molecular pathology of von Hippel-Lindau disease and the VHL tumour suppressor gene. Expert Rev Mol Med Cambridge University Press, March 19, 2001.
14. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Colch). 1998;94:395-404.
15. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988;71:220-225.
16. Finazzi G, Ruggerl M, Rodeghiero F, et al. Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol. 2000;110:577-583.
17. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol 1975;12:339-351.
18. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1214 patients followed for 20 years. Ann Int Med. 1995;123:856-664.
19. Spivak JL. Polycythemia vera: myths, mechanisms and management. Blood. 2002;100:4272-4290.
20. Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol. 2001;38:10-20.
21. Shibata J, Hasegawa J, Siemens H-J, et al. Hemostasis and coagulation at a hematocrit level of 0.85: functional consequences of erythrocytosis. Blood. 2003;101:4416-4422.
22. Prchal JT, Prchal JF, Semenza GL, Sokol L. Familial polycythemia (letter). Science. 1995;268:1831-2.
23. Schmorl G, Junghanns H. The Human Spine in Health and Disease, 2nd Am. ed. Besemann EF, trans, ed. New York: Grune & Stratton; 1971.
24. Calbet JA. Chronic hypoxia increases blood pressure and noradrenaline spillover in healthy humans. J Physiol. 2003;551(pt 1):379-386.
25. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1-14.
26. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest. 2003;111:600-602.
27. Jaakola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel Lindau ubiqutiylation complex by O2-regulated hydroxylation. Science. 2001;292:48-72.
28. Cook JD, Skikne BS. Serum ferritin: a possible model for the assessment of nutrient stores. Am J Clin Nutr. 1982;35(5 suppl):1180-1185.
29. Los M, Aarsman CJ, Terpstra L, et al. Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. Ann Oncol. 1997;8:1015-1022.
30. Niemela M, Maenpaa H, Salven P, et al. Interferon α-2a therapy in 18 hemangioblastomas. Clin Cancer Res. 2000;7:510-516.
31. Li B, Ogasawara AK, Yang R, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002;39:1095-1100.
32. Henry TD, Rocha-Singh K, Isner JM, et al. Intracoronary administration of recombinant human vascular andothelial growth factor to patients with coronary artery disease. Am Heart J 2001;142:872-880.
33. Shoab SS, Scurr JH, Coleridge-Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg. 1998;28:535-540.
34. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A. 2001;98:1583-1588.
35. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000;102:898-901.
36. Chang J, Most D, Bresnick S, et al. Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg. 1999;103:1-9.
37. Walter JW, North PE, Waner M, et al. Somatic mutation of vascular endothelial growth factor receptors in Juvenile hemangioma. Genes Chromosomes Cancer. 2002;33:295-303.
38. Michel T, Feron O. Perspective series. Nitric oxide and nitric oxide synthases. Nitric oxide synthases: which, where, how, and why. J Clin Invest. 1997;100:2146-2152.
39. Palmer LA, Semenza GL, Stoler MH, Johns RA. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol. 1998;274(2 pt 1):L212-L219.
40. Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Association with venous thromboembolism. Arch Pathol Lab Med. 2002;126:1401-1404.
41. Clifford SC, Cockman ME, Smallwood AC, et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet. 2001;10:1029-1038.
42. Kondo K, Kico J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237-246.
43. Tumer KJ, Moore JW, Jones A, et al. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 2002;62:2957-2961.